Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.94 | N/A | +10.46% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.94 | N/A | +10.46% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's strategic direction. They emphasized the importance of innovation and maintaining a strong pipeline.
Management highlighted strong performance in key therapeutic areas.
They noted ongoing investments in research and development to drive future growth.
Bristol Myers Squibb's earnings report shows a solid EPS beat, which contributed to a slight increase in stock price. The positive surprise indicates that the company is performing better than expected in terms of profitability. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Apr 23, 2018